Multiple Sclerosis: Update Bulletin #1 [February 2018]

  • ID: 4521371
  • Newsletter
  • FirstWord Publishing
1 of 2

This edition presents key opinion leader (KOL) views on recent developments in the multiple sclerosis (MS) market. Topics covered include: Roche’s announcement that Ocrevus (ocrelizumab) has been approved by the European Commission as a treatment for RRMS and PPMS; Mylan announcing the UK launch of Brabio (glatiramer acetate injection; 40 mg/ml), a generic version of Copaxone; as well as Merck KGaA’s potential FDA resubmission for Mavenclad (cladribine tablets) as a therapy for relapsing forms of MS.

Business Questions:
  • How is Ocrevus expected to be prescribed once launched?
  • Which agents are anticipated to lose market share as a result of Ocrevus’ launch?
  • How do KOLs view Brabio and how successful is it likely to be?
  • How do KOLs view Mavenclad, and how successful has the European launch been?
  • How is Mavenclad currently prescribed?
Note: Product cover images may vary from those shown
2 of 2


3 of 2
Note: Product cover images may vary from those shown